Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019
Summary
GlobalData, the industry analysis specialist, has released its new report, “Cytomegalovirus (CMV) Infections - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Cytomegalovirus (CMV) Infections Therapeutics market. The report identifies the key trends shaping and driving the global Cytomegalovirus (CMV) Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Cytomegalovirus (CMV) Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Cytomegalovirus (CMV) Infections Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Cytomegalovirus (CMV) Infections Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Cytomegalovirus (CMV) Infections Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Cytomegalovirus (CMV) Infections Therapeutics market.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Cytomegalovirus (CMV) Infections Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Cytomegalovirus (CMV) Infections Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Cytomegalovirus (CMV) Infections Therapeutics market landscape? Identify, understand and capitalize.
Pathology Industry in France
Table of Contents
1 Table of CContents 5
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
3 Disease Overview 10
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.1.3 Risk Factors 13
3.2 Epidemiology 13
3.2.1 CMV Prevalence in General Population 13
3.2.2 CMV Prevalence in At-Risk Populations 14
3.3 Symptoms 15
3.4 Diagnosis and Referral 15
3.4.1 CMV DNA PCR 15
3.4.2 Conventional viral cultures of tissue biopsy or bodily fluids 15
3.4.3 Shell vial culture 16
3.4.4 CMV serology 16
3.4.5 Histopathologic exam with in-situ hybridization 16
3.4.6 Retinal examination using an indirect ophthalmoscope 16
3.4.7 PP65 antigenemia test 16
3.4.8 Referral 17
3.5 Treatment Guidelines 18
3.6 Disease Management 19
4 Competitive Assessment 21
4.1 Overview 21
4.2 Strategic Competitor Assessment 21
4.3 Product Profiles for the Major Marketed Products 25
4.3.1 Ganciclovir sodium 25
4.3.2 Valcyte (valganciclovir) 27
4.3.3 CMV-IGIV 29
4.3.4 Cidofovir 30
4.3.5 Foscarnet 31
4.3.6 Summary of Marketed Drugs 33
5 Opportunity and Unmet Need 34
5.1 Overview 34
5.2 Unmet Needs 37
5.2.1 Unmet Need: Safety 37
5.2.2 Unmet Need: Efficacy 37
5.2.3 Unmet Need: Prophylactic Vaccine 37
5.2.4 Unmet Need: Therapeutic Vaccine 37
5.2.5 Unmet Need: Patient Compliance 38
5.2.6 Unmet Need: Patient Awareness 38
5.2.7 Unmet Need: Physician Education 38
5.2.8 Unmet Need: Early Diagnosis of CMV in Pregnant Women and Transplant Patients 39
5.2.9 Unmet Need: Drug Resistance with Currently Available Antiviral Drugs 39
5.3 Opportunities 39
5.3.1 Opportunity: Vaccine Development Remains a Major Opportunity 39
5.3.2 Opportunity: Addressing Patient Compliance for Long-Term Therapy 39
5.3.3 Opportunity: Generating Physician and Patient Awareness 40
6 Pipeline Assessment 41
6.1 Overview 41
6.2 Strategic Pipeline Assessment 41
6.3 Pipeline Analysis by Phase of Development 42
6.3.1 Phase III Clinical Pipeline 42
6.3.2 Phase II Clinical Pipeline 42
6.3.3 Phase I Pipeline 43
6.3.4 Pre-clinical Pipeline 43
6.3.5 Discovery Pipeline 44
6.4 Pipeline by Mechanism of Action 44
6.5 Technology Trends Analytical Framework 46
6.6 Most Promising Drugs in Clinical Development 48
6.7 Most Promising Drug Profiles 49
6.7.1 TransVax 49
6.7.2 AIC246 52
6.7.3 Maribavir 54
6.7.4 CMX001 56
7 Clinical Trial Mapping 58
7.1 Clinical Trials by Region/Country (US, 5EU and Japan) 58
7.2 Clinical Trials by Phase 59
7.3 Clinical Trials by Trial Status 59
7.4 Clinical Trials by Prominent Sponsors 60
8 Current and Future Players 61
8.1 Trends in Corporate Strategy 61
8.2 Company Profiles 62
8.2.1 F. Hoffmann-La Roche (Roche) 62
8.2.2 Vical 63
8.2.3 AiCuris 65
8.2.4 ViroPharma 66
8.2.5 Chimerix 67
9 Licensing and Partnership Deals 69
9.1 Overview 69
9.2 Key Deals and Alliances in the Past 18 Months 69
10 Market Outlook 70
10.1 Seven Major Markets Overview 70
10.2 Regional Analysis 73
10.2.1 US 73
10.2.2 France 74
10.2.3 Germany 75
10.2.4 Italy 76
10.2.5 Spain 77
10.2.6 UK 77
10.2.7 Japan 78
10.3 Key Events 79
10.4 Drivers and Barriers 79
10.4.1 Drivers for the CMV Infections Market 80
10.4.2 Barriers for the CMV Infections Market 80
11 Appendix 82
11.1 Bibliography 82
11.2 Abbreviations 86
11.3 Methodology 87
11.3.1 Coverage 87
11.3.2 Secondary Research 87
11.3.3 Forecasting Methodology 88
11.3.4 Primary Research 91
11.3.5 Expert Panel Validation 92
11.4 Physicians and Specialists Included in this Study 92
11.5 About the Authors 92
11.5.1 Analysts 92
11.6 About GlobalData 93
11.7 Contact Us 93
11.8 Disclaimer 93
List of Tables
Table 1: Pre-transplant Serologic Status and Relative Risk 11
Table 2: Total Prevalent Cases of CMV Infection in the General Population in the Major Markets (millions), 2011–2019 13
Table 3: Total Prevalent Cases in HSCT and SOT Recipients, Infants and HIV Patients with CMV Infection in the Major Markets, 2011–2019 14
Table 4: Cytomegalovirus Assay Sensitivities and Predictive Values 16
Table 5: Treatment Guidelines for Cytomegalovirus 18
Table 6: Leading Treatments for Cytomegalovirus Infections, 2012 22
Table 7: Ganciclovir Sodium SWOT Analysis, 2012 26
Table 8: Product Profile – Valcyte 27
Table 9: Trial Efficacy Details, Valcyte 28
Table 10: Valcyte SWOT Analysis, 2012 29
Table 11: CMV-IGIV SWOT Analysis, 2012 30
Table 12: Cidofovir SWOT Analysis, 2012 31
Table 13: Foscarnet SWOT Analysis, 2012 32
Table 14: Summary of Marketed Drugs, 2012 33
Table 15: Overall Unmet Needs – Current Level of Attainment (Prophylactic) 35
Table 16: Overall Unmet Needs – Current Level of Attainment (Therapeutic) 36
Table 17: Cytomegalovirus Infections Market, Phase III Pipeline, 2012 42
Table 18: Cytomegalovirus Infections Market, Phase II Pipeline, 2012 42
Table 19: Cytomegalovirus Infections Market, Phase I Pipeline, 2012 43
Table 20: Cytomegalovirus Infections Market, Pre-clinical Pipeline, 2012 43
Table 21: Cytomegalovirus Infections Market, Discovery Pipeline, 2012 44
Table 22: Comparison of Mechanisms of Actions in Development for Cytomegalovirus Infection, 2012 45
Table 23: Cytomegalovirus Infections Market, Global, Most Promising Drugs in Clinical Development, 2012 48
Table 24: Product Profile – TransVax 49
Table 25: TransVax SWOT Analysis, 2012 51
Table 26: AIC246 SWOT Analysis, 2012 53
Table 27: Maribavir SWOT Analysis, 2012 55
Table 28: CMX001 SWOT Analysis, 2012 57
Table 29: Cytomegalovirus Infections, Global, Clinical Trials by Phase, 2012 59
Table 30: Cytomegalovirus Infections, Global, Clinical Trials by Status of Development, 2012 59
Table 31: Cytomegalovirus Infections, Overall Sponsor Mix, 2012 60
Table 32: Key Companies in the Cytomegalovirus Infections Market, 2012 61
Table 33: Roche’s Cytomegalovirus Infections Portfolio Assessment, 2012 62
Table 34: Roche’s Cytomegalovirus Infections Market SWOT Analysis, 2012 63
Table 35: Vical’s Cytomegalovirus Infections Portfolio Assessment, 2012 64
Table 36: Vical’s Cytomegalovirus Infections Market SWOT Analysis, 2012 64
Table 37: AiCuris’ Cytomegalovirus Infections Portfolio Assessment, 2012 65
Table 38: AiCuris’ Cytomegalovirus Infections Market SWOT Analysis, 2012 66
Table 39: ViroPharma’s Cytomegalovirus Infections Portfolio Assessment, 2012 66
Table 40: ViroPharma’s Cytomegalovirus Infections Market SWOT Analysis, 2012 67
Table 41: Chimerix’s Cytomegalovirus Infections Portfolio Assessment, 2012 67
Table 42: Chimerix’s Cytomegalovirus Infections Market SWOT Analysis, 2012 68
Table 43: Strategic Deals and Alliances for Cytomegalovirus Infections, 2012 69
Table 44: Sales Forecasts ($m) for Cytomegalovirus Infections Market in the Seven Major Markets, 2011–2019 72
Table 45: Sales Forecasts ($m) for Cytomegalovirus Infections in the United States, 2011–2019 74
Table 46: Sales Forecasts ($m) for Cytomegalovirus Infections in France, 2011–2019 74
Table 47: Sales Forecasts ($m) for Cytomegalovirus Infections in Germany, 2011–2019 75
Table 48: Sales Forecasts ($m) for Cytomegalovirus Infections in Italy, 2011–2019 76
Table 49: Sales Forecasts ($m) for Cytomegalovirus Infections in Spain, 2011–2019 77
Table 50: Sales Forecasts ($m) for Cytomegalovirus Infections in the UK, 2011–2019 78
Table 51: Sales Forecasts ($m) for Cytomegalovirus Infections in Japan, 2011–2019 78
Table 52: Key Events Impacting Sales for Cytomegalovirus Infections, 2012 79
Table 53: Cytomegalovirus Infections Market – Drivers and Barriers, 2012 79
Table 54: Key Launch Dates 89
Table 55: Key Patent Expiries 89
List of Figures
Figure 1: Cytomegalovirus Infection in Organ Transplant Patients 11
Figure 2: Referral Pathway for Cytomegalovirus Infection 17
Figure 3: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections (Prophylactic) Market, 2012 23
Figure 4: Strategic Competitor Assessment of Marketed Products in Cytomegalovirus Infections (Therapeutics) Market, 2012 24
Figure 5: Opportunity and Unmet Need in the Cytomegalovirus Infections (Prophylactic) Market, 2012 35
Figure 6: Opportunity and Unmet Need in the Cytomegalovirus Infections (Therapeutic) Market, 2012 36
Figure 7: Cytomegalovirus Infections Market, Clinical Pipeline by Mechanism of Action (%), 2012 45
Figure 8: Technology Trends Analytics Framework, 2012 46
Figure 9: Technology Trends Analytics Framework – Unmet Need Gap Analysis, 2012 47
Figure 10: Cytomegalovirus Infections, Global, Clinical Trials by Country, 2012 58
Figure 11: Cytomegalovirus Infections – Leading Companies Participating in Clinical Trials, 2012 60
Figure 12: Sales Forecasts ($m) for Cytomegalovirus Prophylactic Market in the Seven Major Markets, 2011–2019 71
Figure 13: Sales Forecasts ($m) for Cytomegalovirus Therapeutic Market in the Seven Major Markets, 2011–2019 71
Figure 14: Seven Major Market Sales for Cytomegalovirus Prophylactic Market by Region, 2011–2019 72
Figure 15: Seven Major Market Sales for Cytomegalovirus Therapeutic Market by Region, 2011–2019 73
Companies Mentioned
F. Hoffmann-La Roche (Roche)
Vical
AiCuris
ViroPharma
Chimerix
